Cargando…
Therapeutic interventions in severe asthma
The present paper addresses severe asthma which is limited to 5-10% of the overall population of asthmatics. However, it accounts for 50% or more of socials costs of the disease, as it is responsible for hospitalizations and Emergency Department accesses as well as expensive treatments. The recent i...
Autores principales: | Canonica, Giorgio Walter, Senna, Gianenrico, Mitchell, Patrick D., O’Byrne, Paul M., Passalacqua, Giovanni, Varricchi, Gilda |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5125042/ https://www.ncbi.nlm.nih.gov/pubmed/27942351 http://dx.doi.org/10.1186/s40413-016-0130-3 |
Ejemplares similares
-
Reslizumab and Eosinophilic Asthma: One Step Closer to Precision Medicine?
por: Varricchi, Gilda, et al.
Publicado: (2017) -
Anti-Interleukin 5 (IL-5) and IL-5Ra Biological Drugs: Efficacy, Safety, and Future Perspectives in Severe Eosinophilic Asthma
por: Bagnasco, Diego, et al.
Publicado: (2017) -
Mepolizumab in the management of severe eosinophilic asthma in
adults: current evidence and practical experience
por: Varricchi, Gilda, et al.
Publicado: (2016) -
Sex Differences in Severe Asthma: Results From Severe Asthma Network in Italy-SANI
por: Senna, Gianenrico, et al.
Publicado: (2020) -
Frequency of Tiotropium Bromide Use and Clinical Features of Patients with Severe Asthma in a Real-Life Setting: Data from the Severe Asthma Network in Italy (SANI) Registry
por: Puggioni, Francesca, et al.
Publicado: (2020)